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Abstract
Mitral regurgitation is a common valvular heart disease and its prevalence is expected to increase with popu-
lation ageing. Percutaneous techniques for the treatment of mitral regurgitation are emerging as an alternative 
therapeutic option. However, the mitral valve is a complex structure, and a comprehensive understanding of 
the anatomy of the mitral valve apparatus and its surrounding structures is crucial for a correct selection of 
















Mitral regurgitation (MR) is increasingly prevalent despite the 
reduced incidence of rheumatic disease, and its prevalence is 
expected to increase due to population ageing. Approximately 10% 
of people ≥75 years have significant MR, and these patients have 
decreased survival1.
The mitral valve (MV) apparatus is a complex anatomical and 
functional structure2. Echocardiography in two and three dimen-
sions is the clinical tool of choice for assessment of the MV. 
Two-dimensional (2D) echocardiography and especially three-
dimensional (3D) echocardiography have provided detailed 
morphologic and functional assessment, allowing a better under-
standing of the MV apparatus.
MR can be classified as organic or primary MR when the under-
lying disorder is intrinsic to one of the components of the MV, and 
functional or secondary when the MR is due to subvalvular or val-
vular deformations caused by left ventricular (LV) remodelling and 
dysfunction despite a structurally normal MV3.
In patients with severe chronic symptomatic MR or asymptomatic 
MR but recent onset of atrial fibrillation (AF), pulmonary hyperten-
sion or LV dysfunction, surgery is the treatment of choice, MV repair 
being preferable to replacement when feasible. The treatment of func-
tional MR remains controversial4. However, one half of patients with 
severe MR are not referred for surgery, mainly due to advanced age, 
LV dysfunction or the presence of comorbidities5. The development 
of transcatheter MV interventions for the treatment of MR in recent 
years has grown as an alternative therapy for these patients. MV 
interventions, and particularly percutaneous MV repair techniques, 
are based on the same principles as MV surgery, and for each surgi-
cal technique there is a percutaneous equivalent6. Echocardiography 
remains the main imaging technique for MV anatomy assessment, but 
other non-invasive imaging techniques, such as multislice computed 
tomography, may also provide anatomical details facilitating patient 
selection and procedural guidance (e.g., identifying annular and leaf-
let calcifications, or the optimal transseptal or apical puncture site).
Since the MV is a complex structure, for the selection of patients 
and the performance of these procedures, a correct and detailed 
understanding of the anatomy of the MV apparatus and its surround-
ing structures is essential. The aim of this review is to describe the 
anatomy of the MV, focusing on its implications for transcatheter 
MV interventions.
The mitral valve apparatus
The MV apparatus is a complex anatomical and functional struc-
ture, comprising several components (MV annulus, mitral leaflets, 
subvalvular apparatus with tendinous cords and papillary muscles), 
which along with the left ventricle (LV) and atrium are essential for 
integrity and proper valve function2.
1. MITRAL VALVE ANNULUS
1A) ANATOMY
The MV annulus represents the tissue that connects the left atrium 
(LA), LV and mitral leaflets. It is a dynamic, D-shaped orifice7. An area 
Figure 1. Drawing of the mitral subvalvular apparatus. LCS: left 
coronary sinus; NCS: non-coronary sinus; RCS: right coronary 
sinus. (Reproduced with permission)
of fibrous continuity connects the anterior leaflet of the MV with 
the aortic valve, known as the aortic-mitral curtain. The ends of the 
area of fibrous continuity are two rigid structures, the right and left 
fibrous trigones. The right fibrous trigone is contiguous with the 
membranous septum and non-coronary cusps of the aortic valve, 
whereas the left fibrous trigone is contiguous with the left coronary 
cusp (Figure 1). The mitral annulus to aortic annulus angle changes 
dynamically over the cardiac cycle2,8,9. On the other hand, the pos-
terior mitral annulus is more loosely anchored to its surrounding 
tissue. The absence of a fibrous structure as opposed to the aor-
tic-mitral curtain explains why annular dilatation and calcifica-
tion occur most frequently in the posterior segment of the annulus, 
with an increase in the septal-lateral diameter, potentially leading 
to inadequate leaflet coaptation and MR. The MV annulus has a 3D 
saddle-shaped appearance, with elevated anterior and posterior seg-
ments (the highest point corresponding to the anterior segment), 
and lower points represented by the trigones10.
Another relevant anatomical feature which must be considered 
before the performance of a percutaneous procedure involving the 
MV annulus is the coronary sinus. The coronary sinus encircles 
the posterior MV annulus. The great cardiac vein originates at the 
anterior interventricular groove, turning at the atrioventricular junc-
tion, fusing with the oblique vein of the LA to become the coro-
nary sinus. During transcatheter procedures, consideration must be 
given to the fact that interindividual variability of the venous sys-
tem is high, and that the coronary sinus Thebesian valve has signifi-
cant morphological variability which can make the procedure more 
complex11. Variability of the distance between the coronary sinus 
and the MV is substantial, being even greater in cases of significant 
MR due to dilatation of the annulus, when the sinus is lifted away 
from the posterior segment. Attention should also be paid to the cir-












In order to achieve effective and durable results after surgery, annu-
loplasty is a key step14. Several percutaneous techniques have been 
developed in an attempt to remodel the mitral annulus. Transcatheter 
annuloplasty can be performed indirectly via the coronary sinus or 
by approaching the annulus directly via the LA or LV.
Indirect annuloplasty techniques insert a shortening device into 
the coronary sinus, indirectly affecting the posterior mitral annu-
lus geometry due to its close relation with the coronary sinus, in 
an attempt to imitate the effect of a ring in a surgical annuloplasty. 
Several devices such as the CARILLON® Mitral Contour System®15 
(Cardiac Dimensions Inc., Kirkland, WA, USA), MONARC16 
(Edwards Lifesciences, Irvine, CA, USA), and Viacor PTMA 
Device17 (Viacor, Wilmington, MA, USA) have been used.
Several anatomical features should be taken into consideration 
for the success of these devices, such as the presence and morphol-
ogy of the coronary sinus and its relationship with the surround-
ing structures, as well as the anatomy of the circumflex coronary 
artery. Limitations arise from the aforementioned substantial inter-
individual variability between the coronary sinus and the mitral 
annulus itself, which may reduce efficacy. Extrinsic coronary artery 
compression has also been reported13,18, and device fracture due to 
mechanical stress of the coronary sinus has often been reported.
Direct annuloplasty techniques using devices such as the 
Mitralign system (Mitralign, Inc., Tewksbury, MA, USA), the GDS 
Accucinch® System (Guided Delivery Systems, Santa Clara, CA, 
USA) and the Cardioband Annuloplasty System (Valtech Cardio, 
Or Yehuda, Israel) use a direct access to the mitral annulus, in an 
attempt to reproduce surgical annuloplasty more closely and avoid 
the potential limitations of indirect annuloplasty. However, they are 
technically more complicated than indirect annuloplasty, and annu-
lar calcification and the potential for leaflet damage and circumflex 
artery damage are of concern19. Other techniques such as energy-
mediated annuloplasty have also been attempted.
2. MITRAL VALVE LEAFLETS
2A) ANATOMY
The MV is formed by two leaflets, the anterior or aortic leaflet and 
the posterior or mural leaflet. The anterior leaflet has a trapezoid 
shape and is anchored to the fibrous portion of the mitral valve, in 
continuity with the aortic cusps. It is larger, thicker and longer than 
the posterior leaflet, with a wider surface and a shorter base, occu-
pying one third of the annulus circumference. In order to facilitate 
diagnosis and communication, the valve is virtually divided into lat-
eral (A1), central (A2) and medial (A3) scallops. The posterior or 
mural leaflet occupies two thirds of the annulus circumference, but 
is shallower. It has two clefts in its free border, dividing it into lateral 
(P1), central (P2) and medial (P3) scallops. Additional leaflet tissue, 
commissural or junctional, is found at the anterolateral (A1-P1) or 
posteromedial (A3-P3) commissures. The free borders of the leaflets 
are anchored to the subvalvular apparatus via the tendinous cords20,21.
The atrial surface of the leaflets is smooth. A rough zone starts 
approximately 1 cm from the distal leaflet edge. When the leaflets 
Figure 2. Key anatomical eligibility criteria for MitraClip implant. 
(Reproduced with permission from Abbott)
coapt, the irregular soft surface of this zone helps maintain the seal7. 
In systole the leaflets coapt over a height of 8 mm on average, pro-
viding a coaptation reserve in cases of annular dilatation22.
2B) LEAFLET PROCEDURES
The main goal of leaflet procedures is to improve leaflet coaptation 
and reduce the regurgitant orifice. Currently, the most advanced and 
used percutaneous technology for MV repair is the MitraClip sys-
tem (Abbott Vascular, Abbott Park, IL, USA). This catheter-based 
technique is similar to the Alfieri technique, since it implants a clip 
that holds the free edges of the mid portions of the anterior and 
posterior mitral leaflets together, reducing the degree of MR23. The 
MitraClip procedure has been shown to be a feasible and safe alter-
native for patients ineligible for surgery24.
Patient selection should be based on the presence of moderate to 
severe or severe MR, mechanism, aetiology of MR (degenerative 
or functional MR), and several anatomical premises. Therefore, for 
the success of the procedure, anatomical considerations concerning 
the MV have to be taken into account both for selection of patients 
and during the procedure itself, where echocardiography, in two 
and three dimensions, plays an essential role in understanding the 
valve anatomy.
Anatomical criteria determined by transoesophageal echocar-
diography (TEE) were defined in the EVEREST trial25. First of 
all, central jets are the ones which show the best results since the 
MitraClip system creates a double orifice at the level of A2-P2. The 
degree of thickness and calcification of mitral leaflets should also 
be assessed, since the presence of significant calcification especially 
in the grasping area makes the patient unsuitable for the procedure. 
A coaptation length of at least 2 mm and a depth below the mitral 
annular plane of no more than 11 mm must be available. In cases 
of flail leaflets, the gap and the width of the flail segment should 
be no more than 10 and 15 mm, respectively (Figure 2). European 
experience has shown that the MitraClip device can be success-
fully implanted in patients with a more complex MV anatomy. The 
MV area must be more than 4 cm2 in order to avoid mitral stenosis. 
Another important issue to assess is the dimension of the LA and 
interatrial septal morphology, with the presence of patent foramen 
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ovale depicted. The accepted anatomic measurements and charac-
teristics for MitraClip patient selection are summarised in Table 1.
Table 1. Anatomical criteria for selection of patients for MitraClip 
implantation.
Suitable for MC Unsuitable for MC
Aetiology Degenerative or functional. Perforated mitral leaflets or clefts, 
lack of primary and secondary chordal 
support, rheumatic or endocarditic
MV area >4 cm2 Significant mitral stenosis
MR jet Central Eccentric and multiple jets
Calcification None (grasping area) Severe (grasping area)
Specific 
measurements
Flail width <15 mm
Flail gap <10 mm
Coaptation depth <11 mm
Coaptation length >2 mm
Gap between leaflets >2 mm
MC: MitraClip; MR: mitral regurgitation; MV: mitral valve
During the procedure, understanding and consideration of anat-
omy is important for success. In the first step of the procedure, the 
location of the transseptal puncture is crucial, since it must be per-
formed in a posterior and superior location and at a certain distance 
from the valvular plane that enables manipulation of the system 
within the left atrium and grasping of leaflets. To ensure a correct 
location, 2D TEE imaging planes, using a short-axis view at the base 
for anterior-posterior orientation (30-45º), a bicaval view for supe-
rior-inferior orientation (90-120º) and a four-chamber view to iden-
tify the height above the MV, have to be used. Three-dimensional 
echocardiography (3DE), obtaining the whole interatrial septum in 
one view, avoids shifting from one plane to another. Once inside the 
LA, the MitraClip system should be placed above the MV in its mid 
portion, and perpendicular to the line of coaptation, directed towards 
the largest proximal isovelocity surface area (PISA). A 3DE en face 
view of the MV from the LA perspective allows visualisation in one 
image of the whole MV for correct orientation (Figure 3). Once in 
the LV, repositioning may be needed. During grasping of leaflets, 
2D TEE imaging is needed, helping 3DE confirm correct bridging 
between the valves and the clip. Before release, MV gradient and 
orifice area must be evaluated to avoid significant mitral stenosis. In 
cases of unsatisfactory MR reduction, repositioning of the clip or the 
implant of a second clip may be considered26. 
3. TENDINOUS CORDS AND PAPILLARY MUSCLES
The tendinous cords are fibrous strings that originate from the pap-
illary muscle tips and insert into the ventricular aspects of the leaf-
lets27. There is a wide variability in chordal anatomy and branching 
patterns, but cords are classified according to their point of leaf-
let insertion into marginal, intermediate, and basal cords. Marginal 
cords are thinner, insert into the leaflet tips, and have limited exten-
sibility, to avoid leaflet prolapse. Basal cords are thicker and have 
a tighter collagen structure, which makes them more extensible28. 
The basal cords are only found in the posterior leaflet, connecting 
the ventricular surface of the posterior leaflet to the papillary mus-
cles (Figure 1).
The papillary muscles are labelled according to their relation-
ship with mitral commissures as anterolateral and posteromedial 
papillary muscles. They originate from the apical third of the LV 
and protrude into the cavity. The anterolateral papillary muscle has 
a single head and dual blood supply from the circumflex and ante-
rior descending coronary arteries. On the other hand, the postero-
medial papillary muscle is smaller, most commonly has two heads 
and is usually supplied by a single branch of the circumflex or right 
coronary artery, which makes it particularly susceptible to ischae-
mia and the development of ischaemic MR2,7.
The papillary muscle and cord system work together in maintain-
ing an effective systolic coaptation seal. Fibroelastic degeneration 
can induce tissue retraction, making the cords vulnerable to rupture, 
whereas cords inappropriately long in cases of myxomatous degen-
eration can induce mitral prolapse29. 
As already discussed, the MitraClip system is a transcatheter 
approach targeting degenerative and functional MR. With the inten-
tion of connecting the myocardium and the mitral leaflets, artifi-
cial tendinous cords have also been implanted via transseptal or 
transapical approaches30,31.
4. THE LEFT VENTRICLE
The MV is directly connected to the LV via the papillary muscles, 
and therefore changes in the ventricular geometry directly affect 
MV functioning. LV remodelling due to ischaemia, or LV dilatation 
can induce MV tethering due to papillary muscle displacement and 
consequently lack of coaptation and MR32,33.
Catheter techniques such as the percutaneous iCoapsys technique 
based on the Coapsys surgical system (Edwards Lifesciences) have 
been developed. It is a technique which remodels the LV, implanting 
two epicardial pads on both sides of the LV, introducing a transven-
tricular bridge between them through the pericardial space. Indirectly, 
the device potentially reduces the septal-lateral distance, and the pap-
illary muscles are drawn closer to the leaflets, reducing MR34.
Figure 3. A 3DE en face view of the mitral valve from the left atrium 
perspective allows visualisation in one image of the whole mitral 










Percutaneous treatment of MV replacement
Transcatheter aortic valve replacement is already an established 
technique for the treatment of patients with severe aortic stenosis 
and at high surgical risk; however, the development of transcath-
eter MV replacement has not run parallel. This is mainly due to the 
complexity of the MV anatomy, which makes implantation of a per-
cutaneous valve in the mitral position much more challenging than 
in an aortic position. Anchoring is one of the main problems due to 
the asymmetry of the MV annulus, the absence of a single valvular 
plane, and the constant movement of the mitral annulus. The radial 
force could potentially be non-effective and cause complications. 
LV outflow tract obstruction and aortic valve deformation are other 
issues that may lead to complications. The tendinous cords may 
impede positioning, expansion and anchoring. Furthermore, para-
valvular leaks may not be as well tolerated in the mitral position as 
in the aortic position with the development of high gradients.
Currently, despite the potential difficulties, several transcatheter 
MV replacement technologies, transapical or transseptal, are in var-
ious stages of evaluation and development, and are showing prom-
ising results35-37.
Conclusions
With the emergence and development of transcatheter techniques 
for the treatment of MR, special attention has been focused on the 
MV anatomy. The MV is a complex anatomical and functional 
structure, and a comprehensive understanding of the anatomy of 
the MV apparatus and its surrounding structures is crucial for a cor-
rect selection of patients, procedural success and further develop-
ment of these transcatheter technologies.
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